Organon to halt development of pelvic pain drug after mid-stage trial failure
02/07/2025 12:39
July 2 (Reuters) - Organon OGN.N said on Wednesday it will discontinue the development of its experimental pelvic pain drug after it failed to meet the main goal in a mid-stage study. (Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Organon & Co.
See all newsIndia's Sun Pharma misses debt fundraise goal as investors demand higher yields, bankers say
Brief: Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026
India's Persistent Systems plans debut rupee debt sale to fund acquisition, bankers say
India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say
Organon & Co reports results for the quarter ended June 30 - Earnings Summary